Fig. 2

Crystal structure of the FDA-approved VEGFR inhibitors—VEGFR2 complex. The corresponding PDB codes are 3WZE (sorafenib), 3WZD (lenvatinib), 4AGC (axitinib) and 3EFL (motesanib). Hydrogen binding (black) interactions are shown as dashed lines. A The overlap of co-crystal structures of VEGFR2 with sorafenib (green), lenvatinib (orange), axitinib (gray) and motesanib (blue); B–E Binding modes of VEGFR2 with sorafenib, lenvatinib, axitinib and motesanib